2.5 Residual Risk & Follow-Up Medical Plans
Key Takeaways
Residual risk is the remaining probability of being a carrier or of an affected pregnancy after negative or uninformative testing, incorporating detection rate limits and untested variant types
Negative carrier screening never implies zero risk when sensitivity is incomplete, not all genes were assayed, or family-specific variants may be missed by the method
Follow-up plans pair residual numbers with actions: partner testing, expanded sequencing, targeted familial-variant testing, prenatal/preimplantation options, or phenotype-first evaluation
When a familial pathogenic variant is known, test for that variant; a negative generic screening panel does not replace site-specific testing
Document assumptions, detection rates, and recommended next steps so residual-risk counseling is clinically actionable and revisable when new results arrive
2.5 Residual Risk & Follow-Up Medical Plans
Quick Answer: After negative or uninformative results, quote a residual risk (not zero), explain why (detection rate, gene coverage, family-variant mismatch), and attach a follow-up plan: partner testing, expanded/gene-specific testing, site-specific familial testing, prenatal options, or clinical surveillance.
Domain 2A closes the loop from pedigree → Mendelian prior → Bayes → what we do next. A correct residual fraction without a plan is incomplete care and an incomplete exam answer.
What "Residual Risk" Means
Residual risk is the probability that remains after incorporating available negative evidence. Common forms:
| Residual target | Typical setting | Driven by |
|---|---|---|
| Residual carrier probability | Negative carrier screen | Prior × (1 − detection rate), normalized (Bayes) |
| Residual affected-pregnancy risk | Both partners screened or one known carrier | Carrier posteriors × 1/4 (AR) or XL transmission fractions |
| Residual inheritance risk | Negative test for a known familial variant | Lab error, rare sample mix-up, or unrecognized alternate molecular mechanism—usually very low if the assay covers the variant |
| Residual syndromic risk | Uninformative panel/exome | Phenotypic differential still open; consider alternate genes or non-genetic diagnoses |
Say residual risk out loud with the assumptions: ethnicity prior used, detection rate, genes included, and whether a familial variant is known.
Why Negative Screening Is Not Zero
- Imperfect analytic/clinical sensitivity: A 95% detection screen leaves ~5% of carriers undetected before Bayes normalization.
- Limited gene set: A CFTR-only discussion does not clear risk for a phenotypically overlapping different gene.
- Variant-type blind spots: Some methods miss large deletions/duplications, deep intronic variants, or certain structural events unless del/dup or alternate assays are included.
- Wrong test for the family: Panel screening ≠ testing for a known familial pathogenic variant.
- Misassigned prior: Using a pan-ethnic prior when a high-risk ancestry prior applies understates pre-test risk and can distort residual counseling.
Teaching comparison: Prior 1/25, detection 95% → posterior ≈ 1/481 (Section 2.3). Counseling line: "Your chance of being a carrier is now about 1 in 480, not zero."
When to Offer Additional Testing
Offer or escalate testing when residual risk or clinical stakes remain material:
| Situation | Preferred next step | Rationale |
|---|---|---|
| Familial pathogenic variant known in relative | Site-specific testing for that variant | Screening panels can miss the family's variant or report it differently |
| High residual carrier risk + pregnancy plans | Partner carrier testing; consider diagnostic prenatal options if both high risk | Converts individual residual risk into couple risk |
| Negative targeted screen, ancestry or phenotype suggests broader risk | Expanded next-generation sequencing of the relevant gene(s), including del/dup as indicated | Improves detection beyond targeted variant lists |
| XL family, woman with intermediate posterior | Molecular carrier testing of the familial variant or full gene analysis per indication | Clinical/Bayes numbers guide urgency but genotyping clarifies |
| Affected proband never genotyped | Test the affected person first when available | Identifies the familial variant that makes relatives' testing definitive |
| Uninformative VUS-only results | Do not treat VUS as pathogenic; use phenotype, segregation, and lab reclassification pathways | Avoids mismanaging residual risk on uncertain variants |
Worked Couple Residual Risk
Consultand posterior carrier risk after negative screen ≈ 1/480. Partner untested with population carrier risk 1/25.
- Approximate couple both-carrier probability ≈ (1/480)×(1/25) = 1/12,000
- Affected-child risk ≈ (1/12,000)×(1/4) = 1/48,000
If the partner then screens negative with the same 95% detection and a 1/25 prior, his posterior is also ≈ 1/481. Couple affected risk ≈ (1/481)×(1/481)×(1/4) ≈ 1/926,000 (order-of-magnitude teaching). The plan may shift from "partner testing urgently" to "residual risk is very low; still offer education about limitations."
If the partner tests positive, the consultand's residual 1/480 suddenly matters: affected risk ≈ (1/480)×1×(1/4) = 1/1,920, and prenatal/diagnostic options should be reviewed.
Follow-Up Medical Plans Beyond the Laboratory
Residual-risk visits should produce a concrete plan:
- Who to test next (partner, affected relative, parents for phasing/de novo assessment).
- Which assay (site-specific, sequencing, del/dup, biochemical).
- Reproductive options if residual couple risk is unacceptable to the patient (CVS/amnio for known variants, IVF with PGT-M when a familial variant is characterized, donor gametes, adoption)—presented non-directively.
- Phenotype-first surveillance when genotype is uninformative but empiric risks remain (for example, cancer syndrome differentials with uninformative panels—coordinate with Domain 1C concepts).
- Cascade letters / relative contact when a pathogenic variant is found; residual-risk counseling for negatives in the cascade uses site-specific sensitivity near-ceiling, not population screening residuals.
- Recontact policy: detection rates and gene lists change; document that reinterpretation may alter residual risk.
Counseling Language That Matches Board Expectations
- Replace "You're negative, so you're fine" with "Your residual carrier risk is approximately X because the test detects about Y% of carriers."
- Separate assay limitation from patient identity—negative results are about test performance, not personal failure.
- For XL manifesting-carrier nuances or AR mild genotypes, clarify that residual risk discussions concern the defined phenotype in the stem.
- When numbers are tiny, still offer the option of partner testing if it would change decisions; autonomy includes declining further testing.
Integrating the Whole Domain 2A Sequence
| Step | Output |
|---|---|
| Pedigree construction | Who is at risk; inheritance hypothesis |
| Mendelian calculation | Prior risk by position |
| Bayesian update | Posterior given negative/positive conditional data |
| Residual risk + plan | Actionable next medical steps and reproductive counseling |
Exam vignettes often ask for the best next step rather than the fraction alone. If two answers both quote a plausible residual risk, choose the one that pairs the number with the correct assay and relative to test.
High-Yield Pitfalls
- Declaring zero risk after a negative expanded panel when an affected relative's variant remains untested or unknown
- Offering only reassurance when a partner is a known carrier and the consultand has nontrivial residual risk
- Using screening residual-risk math after a negative site-specific test for a known familial variant (those residuals are typically laboratory-quality discussions, not 1/480-style population Bayes)
- Ignoring consanguinity or shared ancestry that raises partner prior above population figures
- Forgetting to update the plan when an affected family member finally receives a molecular diagnosis
Residual risk is the counseling product patients remember. Make it numeric, assumption-transparent, and paired with a follow-up medical plan.
A client completes a negative carrier screen with 95% detection and a Bayesian residual carrier risk of about 1/480. Which counseling statement is most appropriate?
Residual risk is zero because the laboratory reported a negative result
Residual carrier risk is approximately 1/480 because a minority of carriers are missed by a 95% detection assay, and partner-testing decisions should use that posterior
Residual risk equals the original population prior of 1/25 forever after a negative screen
Residual risk applies only if the partner is already known to be a carrier
A pathogenic variant is identified in an affected sibling. The consultand previously had a negative general carrier screening panel for the same disease gene category. What is the best next testing step for the consultand?
Repeat the same general screening panel annually
No further testing is needed because the prior panel was negative
Offer site-specific testing for the familial pathogenic variant
Order mitochondrial genome sequencing as the first-line cascade test
After negative carrier screening, a consultand's residual carrier risk is 1/480 and the partner's untreated population carrier risk is 1/25. What is the approximate risk of an affected child before partner testing (AR model)?
1/480
1/25
1/48,000
1/4
Which follow-up plan element is most essential after quoting a nonzero residual risk?
An actionable next step such as partner testing, site-specific familial testing, expanded sequencing, or a clearly accepted decision to stop testing with documented limitations
A guarantee that residual risk will remain fixed for the client's lifetime regardless of new methods
Automatic prenatal diagnostic testing in every ongoing pregnancy without discussing values or assay limitations
Conversion of all residual-risk clients to research-only testing tracks
Sections you finish are checked off in the contents.